Please assess the completion status of the following clinical trial:

Trial Title: Plerixafor in Diabetic Wound Healing

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Type 1 or type 2 diabetes~* Men of 18-85 years or post-menopausal women \<85 years of age~* Presence of neuroischemic or ischemic diabetic wound(s) of the leg(s) / foot(s) Texas grade 3 or 4, with or without infection.~* Ability to provide informed consent.~Exclusion Criteria:~* Sepsis~* Dialysis or severe chronic kidney disease (eGFR \<20ml/min/1.73 mq)~* Advanced liver disease (defined as cirrhosis or transaminases \>3 times ULN)~* Clinically relevant abnormalities in white blood cell counts at baseline.~* Hematologic disorders (lymphoma, myeloma, acute or chronic leukemia, chronic myeloproliferative disorders)~* Known or highly suspected solid cancer~* Women with childbearing potential~* Known hypersensitivity to Mozobil (Plerixafor or its components)~* Inability to provide informed consent

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- Plerixafor (Type: EXPERIMENTAL): Single subcutaneous injection of Plerixafor (0.24 mg/kg)
- Placebo (Type: PLACEBO_COMPARATOR): Single injection of an equal volume of NaCl solution

Based on this trial design, predict the completion outcome and termination type (if applicable).